DGAP-Adhoc

4SC AG: 4SC provides headline results from Yakult Honsha's Phase II trial of resminostat in combination with sorafenib as first line therapy in liver cancer - Seite 2

as liver, lung, colon, pancreatic, and biliary tract cancer. In new
preclinical models, resminostat further showed promising anti-cancer and
immunomodulatory activity.

About liver cancer (liver cell carcinoma, hepatocellular carcinoma, HCC)

With around 748,000 new cases each year, liver cancer is the fifth most
common type of cancer worldwide and the third most frequent tumor-related
cause of death. In the past three decades alone, the number of new cases
has almost doubled. Liver cancer often remains undetected until it reaches
an advanced stage, resulting in only a slim chance of recovery. The
tyrosine kinase inhibitor sorafenib is the only approved drug-based first-
line therapy for patients with advanced liver cancer which has been shown
to offer a survival benefit in clinical trials.

About the resminostat partnering agreement with Yakult Honsha for Japan

4SC granted an exclusive license to Yakult Honsha for the development and
commercialization of resminostat in Japan in April 2011. 4SC has received
an upfront payment from Yakult Honsha of EUR 6 million and is eligible for
up to approximately EUR 127 million payable upon achieving specified
milestones including clinical and regulatory events in Japan. In addition
to milestone payments, Yakult Honsha will pay 4SC double-digit royalties
linked to product sales of resminostat. Yakult Honsha will be responsible
for all clinical requirements for resminostat development in Japan in
oncology indications.

About 4SC

4SC (www.4sc.com) is a biotechnology company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company's pipeline comprises promising products that are in various stages
of clinical development. 4SC's aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 50 employees at 1 May 2016. 4SC
has been listed on the Prime Standard of the Frankfurt Stock Exchange since
December 2005.

Forward-looking information

This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

Contact

4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, [e-mail], [phone]
Dr. Anna Niedl, [e-mail], [phone]

MC Services
Katja Arnold, [e-mail], [phone]

The Ruth Group
Carol Ruth, [e-mail], [phone]

27.05.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Planegg-Martinsried
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
Tradegate Exchange

End of Announcement DGAP News-Service

---------------------------------------------------------------------------